News
MRNA
145.55
-2.23%
-3.32
Moderna (MRNA) Stock Trades Above Fair Value After Its 479% Run
Simply Wall St · 4h ago
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Barron‘s · 13h ago
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?
The Motley Fool · 14h ago
Buy/Sell: Wall Street’s top 10 stock calls this week
TipRanks · 15h ago
RFK Jr. is probing if U.S. troops died of COVID shots: report
Seeking Alpha · 22h ago
3 Inflated Stocks with Open Questions
Barchart · 1d ago
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
The Motley Fool · 1d ago
Cboe data shows mixed options sentiment in Moderna with shares down 3.87%
TipRanks · 1d ago
Moderna (MRNA) Started A Phase 3 Bird Flu Vaccine Trial
Simply Wall St · 1d ago
Why Moderna's Cancer Vaccine Matters To Investors
Seeking Alpha · 1d ago
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Barron‘s · 1d ago
Moderna slips as Rothschild issues rare Sell rating after cancer vaccine-led rally
Seeking Alpha · 1d ago
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
NASDAQ · 1d ago
Midday Fly By: Nvidia to acquire Hugging Face, Broadcom reports Q3 beat
TipRanks · 1d ago
3 Stocks Whose Competitive Walls Tower Over Nvidia's
The Motley Fool · 1d ago
Moderna's Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 45% Stock Drop
Barron‘s · 1d ago
Why Moderna Stock's Cancer Vaccine Rally Sparked a Rare Sell Rating
Barron‘s · 1d ago
Why Moderna (MRNA) Stock Is Down Today
Barchart · 1d ago
Broadcom upgraded, Ultragenyx downgraded: Wall Street’s top analyst calls
TipRanks · 1d ago
Morning Movers: Victoria’s Secret, Campbell’s sink after quarterly earnings
TipRanks · 1d ago
More
Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).